Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitapivat in Sickle Cell Disease (Phase 2/3, Double-Blind, Randomized, Placebo-Controlled)
2021-001674-34Phase 2Active
- Sponsor
- Agios Pharmaceuticals
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in sickle cell disease (SCD) comparing Mitapivat with Placebo (2 arms). Primary endpoint: Phase 2 Primary Endpoints. Started Dec 2021; status: active.
02
Drugs
mitapivat
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on 2021-001674-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001674-34.